Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/53699
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOoi, Boon Wei.
dc.date.accessioned2013-06-07T01:30:55Z
dc.date.available2013-06-07T01:30:55Z
dc.date.copyright2013en_US
dc.date.issued2013
dc.identifier.urihttp://hdl.handle.net/10356/53699
dc.description.abstractMalaria has been one of the leading causes of death primarily in children in the tropical developing countries. WHO has issued the first line treatment to malaria as the artemisinin-combination therapy (ACT) where artemisinin is used in conjunction of anti-malarial drug to treat malaria. However the high cost of artemisinin due to the low availability has rendered a lot of patients not being able to use such treatment. This triggers a lot of scientists to look into lowering the cost of artemisinin using metabolic engineering. This paper focuses on the developmental effort of scientists in increasing the yield of amorphadiene and artemisinic acid, which are precursors to artemisinin, using various strategies in metabolic engineering, in an attempt to provide seasonless, affordable and continuous supply of artemisinin to the world.en_US
dc.format.extent30 p.en_US
dc.language.isoenen_US
dc.rightsNanyang Technological University
dc.subjectDRNTU::Engineeringen_US
dc.titleMethods used in increasing yield for the production of amorphadiene and artemisinic acid, precursor to anti-malarial drug, artemisinin : a review paper.en_US
dc.typeFinal Year Project (FYP)en_US
dc.contributor.schoolSchool of Chemical and Biomedical Engineeringen_US
dc.description.degreeBachelor of Engineering (Chemical and Biomolecular Engineering)en_US
dc.contributor.supervisor2Song Haoen_US
item.grantfulltextrestricted-
item.fulltextWith Fulltext-
Appears in Collections:SCBE Student Reports (FYP/IA/PA/PI)
Files in This Item:
File Description SizeFormat 
scbe111.pdf
  Restricted Access
778.97 kBAdobe PDFView/Open

Google ScholarTM

Check

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.